Dobi D, Loberto N, Mauri L, Bassi R, Chiricozzi E, Lunghi G
Glycoconj J. 2025; 42(1):1-14.
PMID: 39797966
DOI: 10.1007/s10719-024-10174-7.
Chatterjee P, Moss C, Omar S, Dhillon E, Hernandez Borges C, Tang A
J Fungi (Basel). 2024; 10(9).
PMID: 39330416
PMC: 11433030.
DOI: 10.3390/jof10090656.
Sims-Lucas S, Goetzman E, Kleyman T
J Clin Invest. 2024; 134(13).
PMID: 38949023
PMC: 11213462.
DOI: 10.1172/JCI182329.
Liberski S, Confalonieri F, Cofta S, Petrovski G, Kociecki J
Int J Mol Sci. 2024; 25(12).
PMID: 38928397
PMC: 11203677.
DOI: 10.3390/ijms25126692.
Kamada Y, Ohnishi Y, Nakashima C, Fujii A, Terakawa M, Hamano I
J Cell Biol. 2024; 223(7).
PMID: 38722278
PMC: 11082371.
DOI: 10.1083/jcb.202308003.
Ligand-based virtual-screening identified a novel CFTR ligand which improves the defective cell surface expression of misfolded ABC transporters.
Taniguchi S, Berenger F, Doi Y, Mimura A, Yamanishi Y, Okiyoneda T
Front Pharmacol. 2024; 15:1370676.
PMID: 38666024
PMC: 11043560.
DOI: 10.3389/fphar.2024.1370676.
Recommended Tool Compounds for Modifying the Cystic Fibrosis Transmembrane Conductance Regulator Channel Variants.
Han X, Li D, Zhu Y, Schneider-Futschik E
ACS Pharmacol Transl Sci. 2024; 7(4):933-950.
PMID: 38633590
PMC: 11019735.
DOI: 10.1021/acsptsci.3c00362.
Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis.
Keens T, Hoffman V, Topuria I, Elder K, Cerf S, Mulder K
Heliyon. 2024; 10(7):e28508.
PMID: 38586424
PMC: 10998118.
DOI: 10.1016/j.heliyon.2024.e28508.
UBE3C Facilitates the ER-Associated and Peripheral Degradation of Misfolded CFTR.
Kamada Y, Tateishi H, Nakayamada U, Hinata D, Iwasaki A, Zhu J
Cells. 2023; 12(23).
PMID: 38067172
PMC: 10706245.
DOI: 10.3390/cells12232741.
Transmembrane Helices 7 and 8 Confer Aggregation Sensitivity to the Cystic Fibrosis Transmembrane Conductance Regulator.
Kleizen B, de Mattos E, Papaioannou O, Monti M, Tartaglia G, van der Sluijs P
Int J Mol Sci. 2023; 24(21).
PMID: 37958724
PMC: 10648718.
DOI: 10.3390/ijms242115741.
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one allele: 144-week interim results from a 192-week open-label extension study.
Daines C, Tullis E, Costa S, Linnemann R, Mall M, McKone E
Eur Respir J. 2023; 62(6).
PMID: 37945033
PMC: 10701091.
DOI: 10.1183/13993003.02029-2022.
Epithelial Transport in Disease: An Overview of Pathophysiology and Treatment.
Clemente-Suarez V, Martin-Rodriguez A, Redondo-Florez L, Villanueva-Tobaldo C, Yanez-Sepulveda R, Tornero-Aguilera J
Cells. 2023; 12(20).
PMID: 37887299
PMC: 10605148.
DOI: 10.3390/cells12202455.
Reduced Sphingosine in Cystic Fibrosis Increases Susceptibility to Infections.
Schnitker F, Liu Y, Keitsch S, Soddemann M, Verhasselt H, Kehrmann J
Int J Mol Sci. 2023; 24(18).
PMID: 37762308
PMC: 10530875.
DOI: 10.3390/ijms241814004.
Enhancing the performance of a mutant pyrrolysyl-tRNA synthetase to create a highly versatile eukaryotic cell-free protein synthesis tool.
Schlosshauer J, Zemella A, Dondapati S, Thoring L, Meyer M, Kubick S
Sci Rep. 2023; 13(1):15236.
PMID: 37709815
PMC: 10502014.
DOI: 10.1038/s41598-023-42198-8.
Extracellular vesicles from BALF of pediatric cystic fibrosis and asthma patients increase epithelial sodium channel activity in small airway epithelial cells.
Al-Humiari M, Yu L, Liu L, Nouri M, Tuna K, Denslow N
Biochim Biophys Acta Biomembr. 2023; 1866(1):184219.
PMID: 37634857
PMC: 11632644.
DOI: 10.1016/j.bbamem.2023.184219.
Infection, Allergy, and Inflammation: The Role of in Cystic Fibrosis.
Poore T, Zemanick E
Microorganisms. 2023; 11(8).
PMID: 37630573
PMC: 10458351.
DOI: 10.3390/microorganisms11082013.
A Proteomic Survey of the Cystic Fibrosis Transmembrane Conductance Regulator Surfaceome.
Iazzi M, Sadeghi S, Gupta G
Int J Mol Sci. 2023; 24(14).
PMID: 37511222
PMC: 10380767.
DOI: 10.3390/ijms241411457.
YES1 Kinase Mediates the Membrane Removal of Rescued F508del-CFTR in Airway Cells by Promoting MAPK Pathway Activation via SHC1.
Barros P, Matos A, Matos P, Jordan P
Biomolecules. 2023; 13(6).
PMID: 37371529
PMC: 10296715.
DOI: 10.3390/biom13060949.
Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis.
Olivier M, Kavvalou A, Welsner M, Hirtz R, Strassburg S, Sutharsan S
Front Pharmacol. 2023; 14:1176815.
PMID: 37229253
PMC: 10203630.
DOI: 10.3389/fphar.2023.1176815.
The STING/TBK1/IRF3/IFN type I pathway is defective in cystic fibrosis.
Occhigrossi L, Rossin F, Villella V, Esposito S, Abbate C, DEletto M
Front Immunol. 2023; 14:1093212.
PMID: 36923406
PMC: 10008931.
DOI: 10.3389/fimmu.2023.1093212.